Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study

Background: Patients with refractory mCRC rarely undergo third-line or subsequent treatment. This strategy could negatively impact their survival. In this setting, regorafenib (R) and trifluridine/tipiracil (T) are two key new treatment options with statistically significant improvements in overall...

Descripción completa

Detalles Bibliográficos
Autores principales: Signorelli, Carlo, Calegari, Maria Alessandra, Basso, Michele, Anghelone, Annunziato, Lucchetti, Jessica, Minelli, Alessandro, Angotti, Lorenzo, Zurlo, Ina Valeria, Schirripa, Marta, Chilelli, Mario Giovanni, Morelli, Cristina, Dell’Aquila, Emanuela, Cosimati, Antonella, Gemma, Donatello, Ribelli, Marta, Emiliani, Alessandra, Corsi, Domenico Cristiano, Arrivi, Giulia, Mazzuca, Federica, Zoratto, Federica, Morandi, Maria Grazia, Santamaria, Fiorenza, Saltarelli, Rosa, Ruggeri, Enzo Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296859/
https://www.ncbi.nlm.nih.gov/pubmed/37366896
http://dx.doi.org/10.3390/curroncol30060413

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296859/
https://www.ncbi.nlm.nih.gov/pubmed/37366896
http://dx.doi.org/10.3390/curroncol30060413

Ejemplares similares